Anti-CD20 monoclonal antibodies: reviewing a revolution
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2018-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2018.1508624 |
| _version_ | 1797677415944683520 |
|---|---|
| author | J. M. L. Casan J. Wong M. J. Northcott S. Opat |
| author_facet | J. M. L. Casan J. Wong M. J. Northcott S. Opat |
| author_sort | J. M. L. Casan |
| collection | DOAJ |
| description | Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of autoimmune diseases. Multiple iterations of these agents have been investigated and are routinely used in clinical practice. In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab. |
| first_indexed | 2024-03-11T22:44:55Z |
| format | Article |
| id | doaj.art-7739514f49694e80a4a21a8f52a8d86c |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:44:55Z |
| publishDate | 2018-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-7739514f49694e80a4a21a8f52a8d86c2023-09-22T08:38:23ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2018-12-0114122820284110.1080/21645515.2018.15086241508624Anti-CD20 monoclonal antibodies: reviewing a revolutionJ. M. L. Casan0J. Wong1M. J. Northcott2S. Opat3Monash HealthMonash HealthMonash HealthMonash HealthSince the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice. Additionally, the potent efficacy of these agents in depleting the B cell compartment has been used in the management of a broad array of autoimmune diseases. Multiple iterations of these agents have been investigated and are routinely used in clinical practice. In this review, we will discuss the physiology of CD20 and its attractiveness as a therapeutic target, as well as the pharmacology, pre-clinical and clinical data for the major anti-CD20 monoclonal antibodies: rituximab, obinutuzumab and ofatumumab.http://dx.doi.org/10.1080/21645515.2018.1508624monoclonal antibodycd20rituximabobinutuzumabimmunotherapylymphoma |
| spellingShingle | J. M. L. Casan J. Wong M. J. Northcott S. Opat Anti-CD20 monoclonal antibodies: reviewing a revolution Human Vaccines & Immunotherapeutics monoclonal antibody cd20 rituximab obinutuzumab immunotherapy lymphoma |
| title | Anti-CD20 monoclonal antibodies: reviewing a revolution |
| title_full | Anti-CD20 monoclonal antibodies: reviewing a revolution |
| title_fullStr | Anti-CD20 monoclonal antibodies: reviewing a revolution |
| title_full_unstemmed | Anti-CD20 monoclonal antibodies: reviewing a revolution |
| title_short | Anti-CD20 monoclonal antibodies: reviewing a revolution |
| title_sort | anti cd20 monoclonal antibodies reviewing a revolution |
| topic | monoclonal antibody cd20 rituximab obinutuzumab immunotherapy lymphoma |
| url | http://dx.doi.org/10.1080/21645515.2018.1508624 |
| work_keys_str_mv | AT jmlcasan anticd20monoclonalantibodiesreviewingarevolution AT jwong anticd20monoclonalantibodiesreviewingarevolution AT mjnorthcott anticd20monoclonalantibodiesreviewingarevolution AT sopat anticd20monoclonalantibodiesreviewingarevolution |